Neoadjuvant chemotherapy plus surgery for high-risk advanced gastric cancer: long-term results of KDOG1001 trial.

Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / therapeutic use Cisplatin / administration & dosage Docetaxel / administration & dosage Female Gastrectomy Humans Lymph Node Excision Lymphatic Metastasis Male Middle Aged Neoadjuvant Therapy Neoplasm Invasiveness Prospective Studies Stomach Neoplasms / drug therapy Survival Rate

Gastrectomy Linitis plastica Lymphatic metastasis Neoadjuvant chemotherapy Stomach neoplasm

Journal

Langenbeck's archives of surgery

ISSN: 1435-2451

Titre abrégé: Langenbecks Arch Surg

Pays: Germany

ID NLM: 9808285

Informations de publication

Date de publication:
Sep 2020

Historique:

received: 30 04 2020

accepted: 29 06 2020

pubmed: 4 7 2020

medline: 20 7 2021

entrez: 4 7 2020

Statut: ppublish

Résumé

The purpose of this study is to evaluate the long-term survival outcomes of KDOG1001 trial after a minimum follow-up of 3 years. Patients with bulky N2 lymph nodes, linitis plastica (type 4), or large ulcero-invasive-type tumors (type 3) received up to four 28-day cycles of DCS neoadjuvant chemotherapy (docetaxel at 40 mg/m From May 2010 through January 2017, 40 patients were enrolled. All included patients underwent neoadjuvant chemotherapy with DCS followed by gastrectomy with D2 lymphadenectomy, and 32 (80%) completed adjuvant S-1 therapy for 1 year. After a median follow-up for surviving patients of 68 months at the last follow-up in January 2020, 3-year overall survival rate was 77.5% (95% confidence interval 62.1-87.9%), while 3-year relapse-free survival rate was 62.5% (95% confidence interval 46.8-76.0%). Neoadjuvant chemotherapy with 4 cycles of DCS followed by D2 gastrectomy plus adjuvant S-1 was associated with relatively good long-term oncologic outcomes for patients with the high-risk gastric cancer.

Identifiants

DOI: 10.1007/s00423-020-01924-w PMID: 32617667

pubmed: 32617667

doi: 10.1007/s00423-020-01924-w

pii: 10.1007/s00423-020-01924-w

doi:

Substances chimiques

Docetaxel 15H5577CQD

Cisplatin Q20Q21Q62J

Types de publication

Clinical Trial, Phase II Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

777-785

Références

Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H, Tsujinaka T, Nashimoto A, Fukushima N, Tsuburaya A, on behalf of the Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group (2013) Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 107:741–745. https://doi.org/10.1002/jso.23301

doi: 10.1002/jso.23301 pubmed: 23400787

Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, Oshita H, Ito S, Kawashima Y, Fukushima N (2009) Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 96:1015–1022. https://doi.org/10.1002/bjs.6665

doi: 10.1002/bjs.6665 pubmed: 19644974

Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M, on behalf of the Stomach Cancer Study Group of the Japan Clinical Oncology Group (2014) Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101:653–660. https://doi.org/10.1002/bjs.9484

doi: 10.1002/bjs.9484 pubmed: 24668391

Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group. J Clin Oncol 24:4991–4997. https://doi.org/10.1200/JCO.2006.06.8429

doi: 10.1200/JCO.2006.06.8429 pubmed: 17075117

Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, Nakatani K, Naruke A, Katada C (2012) A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol 69:407–413. https://doi.org/10.1007/s00280-011-1701-1

doi: 10.1007/s00280-011-1701-1 pubmed: 21796483

Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, Ema A, Ushiku H, Wada T, Washio M, Watanabe A, Higuchi K, Tanabe S, Koizumi W, Watanabe M, Yamashita K (2018) A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer 22:598–606. https://doi.org/10.1007/s10120-018-0884-0

doi: 10.1007/s10120-018-0884-0 pubmed: 30284080

Sano T, Kodera Y (2011) Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14:113–123. https://doi.org/10.1007/s10120-011-0042-4

doi: 10.1007/s10120-011-0042-4

Sano T, Kodera Y (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112. https://doi.org/10.1007/s10120-011-0041-5

doi: 10.1007/s10120-011-0041-5

Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, Nakamori M, Onaya H, Sasako M (2017) A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer 20:322–331. https://doi.org/10.1007/s10120-016-0619-z

doi: 10.1007/s10120-016-0619-z pubmed: 27299887

Takahari D, Ito S, Mizusawa J et al (2019) Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer 23:293–299. https://doi.org/10.1007/s10120-019-01007-w

doi: 10.1007/s10120-019-01007-w pubmed: 31515693

Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, Miki A, Nemoto H, Sakamaki K, Fukunaga T, Kimura Y, Hirabayashi N, Yoshikawa T (2017) Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol 28:1876–1881. https://doi.org/10.1093/annonc/mdx236

doi: 10.1093/annonc/mdx236 pubmed: 28486692

Nakamura K, Kuwata T, Shimoda T, Mizusawa J, Katayama H, Kushima R, Taniguchi H, Sano T, Sasako M, Fukuda H (2015) Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer 18:597–604. https://doi.org/10.1007/s10120-014-0401-z

doi: 10.1007/s10120-014-0401-z pubmed: 24968818

Hosoda K, Yamashita K, Katada N, Moriya H, Mieno H, Sakuramoto S, Kikuchi S, Watanabe M (2015) Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today 45:68–77. https://doi.org/10.1007/s00595-014-1060-8

doi: 10.1007/s00595-014-1060-8 pubmed: 25352012

De Andrade JP, Mezhir JJ (2014) The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol 110:291–297. https://doi.org/10.1002/jso.23632

doi: 10.1002/jso.23632 pubmed: 24850538

Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Gotoh M, Takagane A, Yabusaki H, Hirabayashi N, Sano T, Sasako M (2018) Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501). J Clin Oncol 36:4046. https://doi.org/10.1200/JCO.2018.36.15_suppl.4046

doi: 10.1200/JCO.2018.36.15_suppl.4046

Bass AJ, Thorsson V, Shmulevich I et al (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209. https://doi.org/10.1038/nature13480

doi: 10.1038/nature13480 pmcid: 4170219

Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS (2017) Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project. Clin Cancer Res 23:4441–4449. https://doi.org/10.1158/1078-0432.CCR-16-2211

doi: 10.1158/1078-0432.CCR-16-2211

Yamada Y, Boku N, Mizusawa J et al (2019) Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4:501–510. https://doi.org/10.1016/S2468-1253(19)30083-4

doi: 10.1016/S2468-1253(19)30083-4 pubmed: 31101534

Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra. Lancet 393:1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1

doi: 10.1016/S0140-6736(18)32557-1 pubmed: 30982686

Kodera Y, Sano T (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20:1–19. https://doi.org/10.1007/s10120-016-0622-4

doi: 10.1007/s10120-016-0622-4

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393. https://doi.org/10.1200/JCO.2011.36.5908

doi: 10.1200/JCO.2011.36.5908 pubmed: 22010012

Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820. https://doi.org/10.1056/NEJMoa072252

doi: 10.1056/NEJMoa072252 pubmed: 17978289

Yoshida K, Kodera Y, Kochi M et al (2019) Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 37:1296–1304. https://doi.org/10.1200/JCO.18.01138

doi: 10.1200/JCO.18.01138 pubmed: 30925125 pmcid: 6524985

Kang Y-K, Yook JH, Park Y-K, Kim YW, Kim J, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Yoo CH, Choi JH, Zang DY, Kim G, Lee Y, Noh SH (2019) Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY). Ann Oncol 30:v876–v877. https://doi.org/10.1093/annonc/mdz394.032

doi: 10.1093/annonc/mdz394.032

Yamashita K, Ema A, Hosoda K, Mieno H, Moriya H, Katada N, Watanabe M (2017) Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy. World J Gastrointest Oncol 9. https://doi.org/10.4251/wjgo.v9.i4.166

Hosoda K, Watanabe M, Yamashita K (2019) Re-emerging role of macroscopic appearance in treatment strategy for gastric cancer. Ann Gastroenterol Surg 3:122–129

doi: 10.1002/ags3.12218